Is human epididymis protein 4 an effective tool for the differential diagnosis of benign and malignant endometrial tumours?

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F16%3A00065590" target="_blank" >RIV/65269705:_____/16:00065590 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/16:00091106

Result on the web

<a href="http://dx.doi.org/10.12892/ejgo3090.2016" target="_blank" >http://dx.doi.org/10.12892/ejgo3090.2016</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.12892/ejgo3090.2016" target="_blank" >10.12892/ejgo3090.2016</a>

Result language

angličtina

Original language name

Is human epididymis protein 4 an effective tool for the differential diagnosis of benign and malignant endometrial tumours?

Original language description

Purpose of investigation: This study was designed to evaluate the use of human epididymis protein 4 (HE4) as a biomarker in the differential diagnosis of malignant and benign endometrial tumours. Materials and Methods: The study, conducted between July 2009 and June 2014, included a total of 150 patients with endometrioid adenocarcinoma and a control group of 150 patients with benign endometrial lesions. The serum of all patients was analyzed with respect to HE4 and CA125 levels. The median and ranges of serum levels were determined in relation to histological results. The statistical analysis procedure employed in this study utilized logarithmic-transformed values of biomarkers and logistic regression. Results: An analysis of two groups of patients with different histologies yielded a statistically significant difference (p-value < 0.05) only in the case of HE4, in which case a cut-off value of 48.5 pmol/l resulted in an achieved sensitivity of 87.8%, a specificity of 56.6%, and a negative predictive value of 81.1%. Conclusion: In combination with clinical and ultrasound findings, HE4 could help with the differentiation of prognostically varied patient groups as well as with the decision-making process associated with the development of individual treatment plans. However, the optimal cut-off for HE4 has not been established yet and further studies are needed.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FK - Gynaecology and obstetrics

OECD FORD branch

—

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

European journal of gynaecological oncology

ISSN

0392-2936

e-ISSN

—

Volume of the periodical

37

Issue of the periodical within the volume

5

Country of publishing house

CA - CANADA

Number of pages

6

Pages from-to

617-621

UT code for WoS article

—

EID of the result in the Scopus database

—